Trinity Biotech Plc (TRIB) 16.55 $TRIB
Shares of TRIB Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 08, 6:01PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 3 months, Trinity Biotech has returned 16.65% as of today's recent price of $16.75.
TRIB: 16.55 (-0.17)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MSA: 51.14 (-0.88), HLS: 37.46 (-1.14), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), TRIB: 16.55 (-0.17), TEVA: 55.92 (-0.92), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Trinity Biotech Down 15.9% Since SmarTrend Downtrend Call (TRIB)
Comtex SmarTrend(R) - Mon Dec 01, 5:30PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.90% as of today's recent price of $16.90.
TRIB: 16.55 (-0.17)
2014-2018 Japanese Hospital Coagulation Testing Market
M2 - Mon Nov 24, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfzkkb/20142018) has announced the addition of the "2014-2018 Japanese Hospital Coagulation Testing Market" report to their offering. Major issues pertaining to the Japanese coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.Volume and sales forecasts for 40 coagulation procedures performed in Japanese hospitals, including typical coagulation daily work loads. Review of current instrumentation technologies, and a feature comparison of leading analyzers.Reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers.Review of coagulation technologies and their potential market applications.Major opportunities for coagulation instruments and consumables.Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for instrument and reagent suppliers. Contains 392 pages and 28 tables Key Topics Covered: - Major Routine and Special Coagulation Tests - Instrumentation Review - Major in Vitro Diagnostic Technologies and Their Potential Applications - Worldwide Market Overview - Design Criteria for Decentralized Testing Products - Alternative Market Penetration Strategies - Potential Market Entry Barriers and Risks Competitive Assessments - Abbott - American Diagnostica - Avocet Medical - Axis-Shield - Beckman Coulter - Becton Dickinson - Bio/Data Corporation - Biosite - Chrono-Log - Corgenix Medical - Diagnostica Stago - Helena Laboratories - HYPEN BioMed - Instrumentation Laboratory - ITC - Nanogen - Roche - Siemens - Sienco - Sysmex - Thermo Fischer - Trinity Biotech - ZyCare For more information visit http://www.researchandmarkets.com/research/rfzkkb/20142018
TRIB: 16.55 (-0.17)
Downtrend Call Working As Trinity Biotech Stock Falls 15.4% (TRIB)
Comtex SmarTrend(R) - Fri Nov 21, 9:54AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.40% as of today's recent price of $17.00.
TRIB: 16.55 (-0.17)
Trinity Biotech Shares Down 15.3% Since SmarTrend's Sell Call (TRIB)
Comtex SmarTrend(R) - Fri Nov 14, 9:37AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.25% as of today's recent price of $17.03.
TRIB: 16.55 (-0.17)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Trinity Biotech Is Up 8.6% (TRIB)
Comtex SmarTrend(R) - Mon Nov 10, 11:43AM CST
When Trinity Biotech (NASDAQ:TRIB) reported earnings two weeks ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $0.20 on sales of $27.3 million. Trinity Biotech actually reported earnings of $0.18 per share on sales of $27.2 million, missing EPS estimates by $0.01 and matching revenue estimates. Since the company's report, shares of Trinity Biotech have risen from $16.05 to $17.43, representing a gain of 8.6% in the past 18 days.
TRIB: 16.55 (-0.17)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MR: 27.56 (-0.63), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), STJ: 66.33 (-0.68), TRIB: 16.55 (-0.17), ABBV: 65.27 (-1.76), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Weakness Seen in Trinity Biotech (TRIB): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:44AM CDT
Shares of Trinity Biotech fell nearly 8% last session and witnessed flat revision in current year estimates in the past few weeks suggest a close watch of the firm in the near future.
ZLTQ: 29.06 (+0.32), PAHC: 31.00 (-0.88), GWPH: 72.41 (+1.18), TRIB: 16.55 (-0.17)
Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 7:28AM CDT
TRIB: 16.55 (-0.17)
More on Trinity Biotech Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 11:22AM CDT
TRIB: 16.55 (-0.17)
Trinity Biotech EPS of $0.19
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:05AM CDT
TRIB: 16.55 (-0.17)
Trinity Biotech Announces Quarter 3 Financial Results and Temporary Suspension of Meritas Troponin Trials
GlobeNewswire - Thu Oct 23, 8:01AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2014. In addition, it announced that it was temporarily suspending its FDA trials for its Meritas Troponin test.
TRIB: 16.55 (-0.17)
Trinity Biotech (TRIB) Downgraded From Buy to Hold
at The Street - Thu Oct 16, 8:14AM CDT
Trinity Biotech (TRIB) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
TRIB: 16.55 (-0.17)
Trinity Biotech plc to Announce Third Quarter Fiscal 2014 Financial Results
GlobeNewswire - Mon Oct 06, 4:45AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2014 on Thursday, October 23, 2014. The Company has scheduled a conference call for that same day, Thursday, October 23, 2014 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
TRIB: 16.55 (-0.17)
Shares of TRIB Down 16.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 08, 6:01PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 3 months, Trinity Biotech has returned 16.65% as of today's recent price of $16.75.
TRIB: 16.55 (-0.17)
5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides
Fredrik Arnold - at Seeking Alpha - Thu Dec 04, 2:40AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MSA: 51.14 (-0.88), HLS: 37.46 (-1.14), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), TRIB: 16.55 (-0.17), TEVA: 55.92 (-0.92), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Trinity Biotech Down 15.9% Since SmarTrend Downtrend Call (TRIB)
Comtex SmarTrend(R) - Mon Dec 01, 5:30PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.90% as of today's recent price of $16.90.
TRIB: 16.55 (-0.17)
2014-2018 Japanese Hospital Coagulation Testing Market
M2 - Mon Nov 24, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfzkkb/20142018) has announced the addition of the "2014-2018 Japanese Hospital Coagulation Testing Market" report to their offering. Major issues pertaining to the Japanese coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.Volume and sales forecasts for 40 coagulation procedures performed in Japanese hospitals, including typical coagulation daily work loads. Review of current instrumentation technologies, and a feature comparison of leading analyzers.Reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers.Review of coagulation technologies and their potential market applications.Major opportunities for coagulation instruments and consumables.Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for instrument and reagent suppliers. Contains 392 pages and 28 tables Key Topics Covered: - Major Routine and Special Coagulation Tests - Instrumentation Review - Major in Vitro Diagnostic Technologies and Their Potential Applications - Worldwide Market Overview - Design Criteria for Decentralized Testing Products - Alternative Market Penetration Strategies - Potential Market Entry Barriers and Risks Competitive Assessments - Abbott - American Diagnostica - Avocet Medical - Axis-Shield - Beckman Coulter - Becton Dickinson - Bio/Data Corporation - Biosite - Chrono-Log - Corgenix Medical - Diagnostica Stago - Helena Laboratories - HYPEN BioMed - Instrumentation Laboratory - ITC - Nanogen - Roche - Siemens - Sienco - Sysmex - Thermo Fischer - Trinity Biotech - ZyCare For more information visit http://www.researchandmarkets.com/research/rfzkkb/20142018
TRIB: 16.55 (-0.17)
Downtrend Call Working As Trinity Biotech Stock Falls 15.4% (TRIB)
Comtex SmarTrend(R) - Fri Nov 21, 9:54AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.40% as of today's recent price of $17.00.
TRIB: 16.55 (-0.17)
Trinity Biotech Shares Down 15.3% Since SmarTrend's Sell Call (TRIB)
Comtex SmarTrend(R) - Fri Nov 14, 9:37AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on September 19th, 2014 at $20.10. In approximately 2 months, Trinity Biotech has returned 15.25% as of today's recent price of $17.03.
TRIB: 16.55 (-0.17)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Trinity Biotech Is Up 8.6% (TRIB)
Comtex SmarTrend(R) - Mon Nov 10, 11:43AM CST
When Trinity Biotech (NASDAQ:TRIB) reported earnings two weeks ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $0.20 on sales of $27.3 million. Trinity Biotech actually reported earnings of $0.18 per share on sales of $27.2 million, missing EPS estimates by $0.01 and matching revenue estimates. Since the company's report, shares of Trinity Biotech have risen from $16.05 to $17.43, representing a gain of 8.6% in the past 18 days.
TRIB: 16.55 (-0.17)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 18.61 (+0.54), VIVO: 16.36 (-0.35), PETS: 13.52 (-0.01), PFE: 30.95 (-0.70), GSK: 42.42 (-0.93), MR: 27.56 (-0.63), SEM: 13.95 (-0.28), PDLI: 7.41 (-0.08), SNN: 32.48 (-0.41), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), STJ: 66.33 (-0.68), TRIB: 16.55 (-0.17), ABBV: 65.27 (-1.76), THRX: 13.39 (-0.37), SNY: 45.16 (-1.05)
Weakness Seen in Trinity Biotech (TRIB): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:44AM CDT
Shares of Trinity Biotech fell nearly 8% last session and witnessed flat revision in current year estimates in the past few weeks suggest a close watch of the firm in the near future.
ZLTQ: 29.06 (+0.32), PAHC: 31.00 (-0.88), GWPH: 72.41 (+1.18), TRIB: 16.55 (-0.17)
Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 7:28AM CDT
TRIB: 16.55 (-0.17)
More on Trinity Biotech Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 11:22AM CDT
TRIB: 16.55 (-0.17)
Trinity Biotech EPS of $0.19
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:05AM CDT
TRIB: 16.55 (-0.17)
Trinity Biotech Announces Quarter 3 Financial Results and Temporary Suspension of Meritas Troponin Trials
GlobeNewswire - Thu Oct 23, 8:01AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2014. In addition, it announced that it was temporarily suspending its FDA trials for its Meritas Troponin test.
TRIB: 16.55 (-0.17)
Trinity Biotech (TRIB) Downgraded From Buy to Hold
at The Street - Thu Oct 16, 8:14AM CDT
Trinity Biotech (TRIB) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
TRIB: 16.55 (-0.17)
Trinity Biotech plc to Announce Third Quarter Fiscal 2014 Financial Results
GlobeNewswire - Mon Oct 06, 4:45AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2014 on Thursday, October 23, 2014. The Company has scheduled a conference call for that same day, Thursday, October 23, 2014 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
TRIB: 16.55 (-0.17)
